Ceribell

About Ceribell

Ceribell is a medical technology company specializing in the rapid detection of neonatal seizures, operating at the intersection of neurology and neonatal care. Founded with a mission to improve outcomes for newborns, the company develops innovative diagnostic tools designed for use in neonatal intensive care units (NICUs). The name "Ceribell" likely reflects a focus on the brain ("Cere") and precision ("Bell"), suggesting a commitment to accurate, timely neurological assessments. Based on its domain and industry focus, Ceribell appears to be a leader in addressing the critical need for early seizure detection in vulnerable newborns. Ceribell's flagship product is the Rapid Neonatal Seizure Detection System, a handheld device that provides immediate, non-invasive brain activity monitoring. This technology enables clinicians to detect subtle seizures within minutes, allowing for faster intervention and treatment compared to traditional methods. The system is designed for neonatologists, pediatric neurologists, and NICU staff, offering features such as real-time alerts, cloud-based data storage, and integration with electronic health records. By targeting healthcare providers in hospitals and academic medical centers, Ceribell aims to bridge the gap between seizure occurrence and clinical response, ultimately reducing long-term neurological deficits in infants. Notably, Ceribell has established itself as a pioneer in this niche market, with its technology adopted by leading NICUs worldwide, underscoring its role in advancing neonatal neuroprotection.